FCSC - Fibrocell Science, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.07
+0.01 (+0.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.06
Open2.04
Bid1.75 x 1000
Ask2.28 x 3000
Day's Range2.04 - 2.16
52 Week Range1.75 - 9.00
Volume103,647
Avg. Volume190,495
Market Cap19.282M
Beta (3Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the third quarter ended September 30, 2018 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EST. “During the third quarter, Fibrocell made important progress with the clinical development of our gene therapy programs focused on rare diseases of the skin and connective tissue,” said John Maslowski, President and Chief Executive Officer of Fibrocell.

  • Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3
    Zacks8 days ago

    Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3

    Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.

  • GlobeNewswire9 days ago

    Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights

    EXTON, Pa., Nov. 08, 2018 -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective.

  • GlobeNewswire23 days ago

    Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced completion of a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the design of a Phase 3 clinical trial protocol of FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The meeting was facilitated by the current data in Fibrocell’s ongoing Phase 1/2 clinical trial of FCX-007 and the recent publication of draft guidance from the FDA in the areas of gene therapy and epidermolysis bullosa.

  • GlobeNewswire2 months ago

    Fibrocell to Present at Upcoming Industry and Investor Conferences

    EXTON, Pa., Sept. 26, 2018 -- Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and.

  • GlobeNewswire2 months ago

    Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) has awarded a $1.4 million clinical trial research grant for Fibrocell’s continued clinical development of FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating, rare skin blistering disease with high mortality. “We are delighted with the FDA’s recognition to support the ongoing progress of our clinical trials of FCX-007,” said John Maslowski, President and Chief Executive Officer of Fibrocell.

  • GlobeNewswire2 months ago

    Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma

    Fibrocell Science, Inc. (FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma—a chronic, debilitating genetic skin disorder with no FDA approved therapies. “Fast Track designation represents an important milestone in advancing clinical development of FCX-013,” said John Maslowski, President and Chief Executive Officer of Fibrocell.

  • ACCESSWIRE3 months ago

    Fibrocell Science, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Fibrocell Science, Inc. (NASDAQ: FCSC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern ...

  • What's in Store for Intrexon (XON) This Earnings Season?
    Zacks4 months ago

    What's in Store for Intrexon (XON) This Earnings Season?

    Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.

  • ACCESSWIRE4 months ago

    Free Technical Research on Evolus and Three More Generic Drugs Equities

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on EOLS sign up now at www.wallstequities.com/registration. On Tuesday, July 24, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.79% and 0.48% higher, respectively at the closing bell, while the NASDAQ Composite stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drugs - Generic equities this morning: Evolus Inc. (EOLS), Fibrocell Science Inc. (NASDAQ: FCSC), Flexion Therapeutics, Inc. (NASDAQ: FLXN), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA).

  • Benzinga6 months ago

    Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 31) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) (Piper Jaffray initiated ...

  • Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy?
    Zacks6 months ago

    Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy?

    Fibrocell Science, Inc. (FCSC) has been struggling lately, but the selling pressure may be coming to an end soon

  • ACCESSWIRE6 months ago

    Blog Exposure - Fibrocell Presented Update on Interim Results and Progress of its Phase-1/2 Clinical Trial of FCX-007 at International Investigative Dermatology Meeting

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Fibrocell Science, Inc. (NASDAQ: FCSC), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FCSC as the Company's latest news hit the wire. On May 21, 2018, the Company presented an update on the interim results and progress of its Phase-1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) at the 7th International Investigative Dermatology (IID) meeting held on May 19, 2018. Active-Investors.com is currently working on the research report for OptiNose, Inc. (NASDAQ: OPTN), which also belongs to the Healthcare sector as the Company Fibrocell Science.

  • Benzinga6 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Fibrocell Science Inc (NASDAQ: FCSC ) stock gained ...

  • Benzinga6 months ago

    Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 16) Abaxis Inc (NASDAQ: ABAX ) (announced a deal to be bought ...